ACTRN12621000426886尚未招募未知
The feasibility and therapeutic efficacy of a two-week low-level laser acupuncture therapy for shoulder and neck pain in office workers: a single-blind, double-armed, randomised controlled trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1) aged between 18-65 years
- •2) working more than 28 h a week with sedentary office work
- •3) moderate to severe SNP (VAS > 5/10 & SF-MPQ > 2/45) for more than three months
排除标准
- •Women who are pregnant, people with cancer, high sensitivity to light, or other symptoms of unknown cause will not be eligible.
研究者
相似试验
已完成
不适用
Clinical investigation of the effectiveness of two bleaching methods with and without light exposureDark tooth shadeDRKS00026670Firma Lornamead GmbH40
已完成
2 期
Efficacy and safety of dual therapy containing vonopranzan and amoxicillin as first line Helicobacter pylori eradication: a randomized, non-inferiority trialHelicobacter pylori infectionJPRN-UMIN000034140Division of Gastroenterology and Hepatology, Department of Medicine,Nihon University School of Medicine335
已完成
2 期
A phase II study on the feasibility and efficacy of preoperative chemoradiotherapy with S-1 for locally advanced rectal cancerrectal cancerJPRN-UMIN000023621Department of Surgery Kindai University Faculty of Medicine42
进行中（未招募）
不适用
Treatment of neuroendocrine tumours with radiolabelled somatostatin analoguesPatients bearing neuroendocrine tumour expressing somatostatin receptors refractory to conventional therapiesMedDRA version: 14.1Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-006234-16-ITISTITUTO NAZIONALE PER LA CURA TUMORI
招募中
2 期
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin*s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHL10025320lymphomaNL-OMON36830HOVO60